ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

AVNR: Avanir Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

AVANIR PHARMACEUTICALS INC (NASD)
AVNR	1.81	0.01	(0.56%)	Vol. 320,917	16:00 ET

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.

General Information

AVANIR PHARM

101 Enterprise Suite 300 Aliso Viejo, CA 92656 Phone: 949 389-6700 Fax: - Web: www.avanir.com Email: ir@avanir.comp

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	September
Last Reported Quarter	09/30/09
Next EPS Date	N/A

Price and Volume Information

Zacks Rank
Yesterday's Close	1.80
52 Week High	4.09
52 Week Low	0.23
Beta	2.53
20 Day Moving Average	671,296.38
Target Price Consensus	N/A

% Price Change
4 Week	-11.71
12 Week	-9.95
YTD	341.25

% Price Change Relative to S&P 500
4 Week	-11.58
12 Week	-14.93
YTD	274.55

Share Information
Shares Outstanding (millions)	78.46
Market Capitalization (millions)	142.02
Short Ratio	1.06
Last Split Date	01/18/2006

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	N/A
Next EPS Report Date	N/A

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-200.00%
vs. Previous Quarter	0.00%

Sales Growth
vs. Previous Year	-77.27%
vs. Previous Quarter:	-27.22%

Price Ratios
Price/Book	9.33
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-
06/30/09	-92.17
03/31/09	-62.56

ROA
09/30/09	-
06/30/09	-54.17
03/31/09	-38.35

Current Ratio
09/30/09	-
06/30/09	5.24
03/31/09	6.54

Quick Ratio
09/30/09	-
06/30/09	5.24
03/31/09	6.54

Operating Margin
09/30/09	-
06/30/09	-461.05
03/31/09	-260.45

Net Margin
09/30/09	-
06/30/09	-460.14
03/31/09	-253.27

Pre-Tax Margin
09/30/09	-
06/30/09	-460.14
03/31/09	-253.27

Book Value
09/30/09	-
06/30/09	0.19
03/31/09	0.25

Inventory Turnover
09/30/09	-
06/30/09	56.97
03/31/09	56.97

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research